M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

Phase 1

Not yet recruiting

Conditions: Refractory Acute Leukemia
Relapsed Acute Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Sorafenib
Drug: Decitabine

First Posted Date: 2024-06-26

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT06474663

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Phase 2

Recruiting

Conditions: Unresectable Melanoma

Interventions: Other: Prebiotic Food-Enriched Diet

First Posted Date: 2024-06-20

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT06466434

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

Phase 1

Not yet recruiting

Conditions: Relapsed Acute Leukemia
Undifferentiated Leukemia
Bi-Phenotypic Leukemia
Refractory Acute Leukemia

Interventions: Drug: Venetoclax
Drug: Hyper-CVAD

First Posted Date: 2024-06-20

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT06466395

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation

Recruiting

Conditions: Allogeneic Transplantation

Interventions: Behavioral: Patient Ancestry Questionnaires

First Posted Date: 2024-06-10

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1200

Registration Number: NCT06450353

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Gemtuzumab
Drug: Ziftomenib

First Posted Date: 2024-06-07

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT06448013

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2

Recruiting

Conditions: Locally Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab
Drug: Cetuximab

First Posted Date: 2024-06-07

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT06448026

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

Phase 1

Recruiting

Conditions: Mutant IDH1 Inhibitor Olutasidenib

Interventions: Drug: Olutasidenib
Drug: Venetoclax
Drug: Decitabine

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT06445959

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Venetoclax
Drug: Q702

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT06445907

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Phase 2

Recruiting

Conditions: SMARCB1-Deficient Malignancies

Interventions: Drug: Ubamatamab
Drug: Cemiplimab

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06444880

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Phase 2

Suspended

Conditions: FGFR2 Fusion
Advanced Cholangiocarcinoma

Interventions: Drug: Pemigatinib
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2024-06-03

Last Posted Date: 2024-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT06439485

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy